subscribeSubscribe
price-trendAsk Us
Essential Pharma acquires European rights to Colobreathe from Teva

Essential Pharma acquires European rights to Colobreathe from Teva
GLOBENEWSWIRE
08 Jan 2024
Share Share
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb®

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb®
PRESS RELEASE
21 Apr 2022
Share Share
EU drug regulators review use of last-resort antibiotic in farming

EU drug regulators review use of last-resort antibiotic in farming
Kate Kelland REUTERS
11 Jan 2016
Share Share
Xellia`s Generic Colistimethate Sodium (Eq 150Mg Base/Vial) Approved in US For Bacterial Infections

Xellia`s Generic Colistimethate Sodium (Eq 150Mg Base/Vial) Approved in US For Bacterial Infections
FDA
03 Jun 2015
Share Share
Heritage Pharmaceuticals, Inc., Ongoing Class II recall of Colistimethate for Injection USP, 150 mg per vial, Rx Only, Manufactured by: Emcure Pharmaceuticals Ltd., Hinjwadi, Pune, India Manufactured for: Heritage Pharmaceuticals Inc. NDC 23155-193-31 because of Lack of Assurance of Sterility: Firm is recalling two injectable products due to concerns with quality control processes.

Heritage Pharmaceuticals, Inc., Ongoing Class II recall of Colistimethate for Injection USP, 150 mg per vial, Rx Only, Manufactured by: Emcure Pharmaceuticals Ltd., Hinjwadi, Pune, India Manufactured for: Heritage Pharmaceuticals Inc. NDC 23155-193-31 because of Lack of Assurance of Sterility: Firm is recalling two injectable products due to concerns with quality control processes.
FDA
25 Mar 2015
Share Share
Heritage Pharmaceuticals Initiates a Nationwide Voluntary Recall of Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial Due to a Lack of Sterility Assurance

Heritage Pharmaceuticals Initiates a Nationwide Voluntary Recall of Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial Due to a Lack of Sterility Assurance
Press Release USFDA
24 Feb 2015
Share Share
Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP

Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP
Press Release SAGENT PHARMACEUTICALS
30 Dec 2014
Share Share